Search Results Search Sort by RelevanceMost Recent Medicine and Society Aug 2019 Does Incorporating Cost-Effectiveness Analysis Into Prescribing Decisions Promote Drug Access Equity? Michael J. DiStefano, MBE and Jonathan S. Levin, MPH Advances in CEA methodology might integrate equity at the cost of transparency. AMA J Ethics. 2019;21(8):E679-685. doi: 10.1001/amajethics.2019.679. Case and Commentary Aug 2019 How Should Physicians Steward Limited Resources While Ensuring That Patients Can Access Needed Medicines? Pete Croughan and Rebekah E. Gee, MD, MPH Louisiana has a subscription model for hepatitis C treatment, but costly medications challenge states’ capacities to cover patients. AMA J Ethics. 2019;21(8):E630-635. doi: 10.1001/amajethics.2019.630. Policy Forum Aug 2019 Why Are Biosimilars Not Living up to Their Promise in the US? Mike Z. Zhai, Ameet Sarpatwari, JD, PhD, and Aaron S. Kesselheim, MD, JD, MPH Overall utilization of the few biosimilars currently available to patients has been limited. AMA J Ethics. 2019;21(8):E668-678. doi: 10.1001/amajethics.2019.668. Original Research Feb 2019 Can AI Help Reduce Disparities in General Medical and Mental Health Care? Irene Y. Chen, Peter Szolovits, PhD, and Marzyeh Ghassemi, PhD As machine learning becomes increasingly common in health care, these systems’ data, algorithms, and recommendations raise critical justice questions. AMA J Ethics. 2019;21(2):E167-179. doi: 10.1001/amajethics.2019.167. Case and Commentary Mar 2020 How Should Organizations Respond to Repeated Noncompliance by Prominent Researchers? Min-Fu Tsan, MD, PhD and Grace L. Tsan, OD IRBs must report human subject research protocol deviations and university leadership might also need to motivate compliance with federal regulations. AMA J Ethics. 2020;22(3):E201-208. doi: 10.1001/amajethics.2020.201. Policy Forum Aug 2020 Revisiting the WHO Analgesic Ladder for Surgical Management of Pain Laura Stone McGuire, MD and Konstantin Slavin, MD A 3-step analgesic ladder was introduced in 1986 and needs change. Surgical interventions could reduce opioid use and motivate expansion of current pain management approaches. AMA J Ethics. 2020;22(8):E695-701. doi: 10.1001/amajethics.2020.695. Case and Commentary May 2022 Should Clinicians Ever Recommend Supplements to Patients Trying to Lose Weight? Melinda M. Manore, PhD, RDN and Megan Patton-Lopez, PhD, RDN Helping patients mitigate their risk of chronic disease is key, but dietary supplements are risky. AMA J Ethics. 2022;24(5):E345-352. doi: 10.1001/amajethics.2022.345. Case and Commentary May 2022 Should Clinicians Prescribe Non-FDA Regulated Dietary Supplements When Caring for Children With Hypovitaminosis D? Ethan A. Mezoff, MD, Hannah Hays, MD, and Ala Shaikhkhalil, MD Children with micronutrient deficiency might need supplementation, sometimes in irregularly high doses. AMA J Ethics. 2022;24(5):E353-360. doi: 10.1001/amajethics.2022.353. Case and Commentary May 2022 How Should Clinicians Respond to Patient Interest in Dietary Supplements to Treat Serious Chronic Illness? Valerie Clinard, PharmD, APh and Jennifer D. Smith, PharmD, BCACP, BC-ADM, CDCES Consumption of over-the-counter vitamins, minerals, and herbals is widespread, but clinicians lack critical information about their use. AMA J Ethics. 2022;24(5):E361-367. doi: 10.1001/amajethics.2022.361. Case and Commentary May 2022 How Does Cognitive Bias Affect Conversations With Patients About Dietary Supplements? Ila M. Harris, PharmD, Christine C. Danner, PhD, and David J. Satin, MD Some allopathic clinicians’ biases influence the information they draw upon to make decisions and offer recommendations. AMA J Ethics. 2022;24(5):E368-375. doi: 10.1001/amajethics.2022.368. Pagination First page « First Previous page ‹ Previous … Page 2 Page 3 Page 4 Page 5 Current page 6 Page 7 Page 8 Page 9 Page 10 … Next page Next › Last page Last »
Medicine and Society Aug 2019 Does Incorporating Cost-Effectiveness Analysis Into Prescribing Decisions Promote Drug Access Equity? Michael J. DiStefano, MBE and Jonathan S. Levin, MPH Advances in CEA methodology might integrate equity at the cost of transparency. AMA J Ethics. 2019;21(8):E679-685. doi: 10.1001/amajethics.2019.679.
Case and Commentary Aug 2019 How Should Physicians Steward Limited Resources While Ensuring That Patients Can Access Needed Medicines? Pete Croughan and Rebekah E. Gee, MD, MPH Louisiana has a subscription model for hepatitis C treatment, but costly medications challenge states’ capacities to cover patients. AMA J Ethics. 2019;21(8):E630-635. doi: 10.1001/amajethics.2019.630.
Policy Forum Aug 2019 Why Are Biosimilars Not Living up to Their Promise in the US? Mike Z. Zhai, Ameet Sarpatwari, JD, PhD, and Aaron S. Kesselheim, MD, JD, MPH Overall utilization of the few biosimilars currently available to patients has been limited. AMA J Ethics. 2019;21(8):E668-678. doi: 10.1001/amajethics.2019.668.
Original Research Feb 2019 Can AI Help Reduce Disparities in General Medical and Mental Health Care? Irene Y. Chen, Peter Szolovits, PhD, and Marzyeh Ghassemi, PhD As machine learning becomes increasingly common in health care, these systems’ data, algorithms, and recommendations raise critical justice questions. AMA J Ethics. 2019;21(2):E167-179. doi: 10.1001/amajethics.2019.167.
Case and Commentary Mar 2020 How Should Organizations Respond to Repeated Noncompliance by Prominent Researchers? Min-Fu Tsan, MD, PhD and Grace L. Tsan, OD IRBs must report human subject research protocol deviations and university leadership might also need to motivate compliance with federal regulations. AMA J Ethics. 2020;22(3):E201-208. doi: 10.1001/amajethics.2020.201.
Policy Forum Aug 2020 Revisiting the WHO Analgesic Ladder for Surgical Management of Pain Laura Stone McGuire, MD and Konstantin Slavin, MD A 3-step analgesic ladder was introduced in 1986 and needs change. Surgical interventions could reduce opioid use and motivate expansion of current pain management approaches. AMA J Ethics. 2020;22(8):E695-701. doi: 10.1001/amajethics.2020.695.
Case and Commentary May 2022 Should Clinicians Ever Recommend Supplements to Patients Trying to Lose Weight? Melinda M. Manore, PhD, RDN and Megan Patton-Lopez, PhD, RDN Helping patients mitigate their risk of chronic disease is key, but dietary supplements are risky. AMA J Ethics. 2022;24(5):E345-352. doi: 10.1001/amajethics.2022.345.
Case and Commentary May 2022 Should Clinicians Prescribe Non-FDA Regulated Dietary Supplements When Caring for Children With Hypovitaminosis D? Ethan A. Mezoff, MD, Hannah Hays, MD, and Ala Shaikhkhalil, MD Children with micronutrient deficiency might need supplementation, sometimes in irregularly high doses. AMA J Ethics. 2022;24(5):E353-360. doi: 10.1001/amajethics.2022.353.
Case and Commentary May 2022 How Should Clinicians Respond to Patient Interest in Dietary Supplements to Treat Serious Chronic Illness? Valerie Clinard, PharmD, APh and Jennifer D. Smith, PharmD, BCACP, BC-ADM, CDCES Consumption of over-the-counter vitamins, minerals, and herbals is widespread, but clinicians lack critical information about their use. AMA J Ethics. 2022;24(5):E361-367. doi: 10.1001/amajethics.2022.361.
Case and Commentary May 2022 How Does Cognitive Bias Affect Conversations With Patients About Dietary Supplements? Ila M. Harris, PharmD, Christine C. Danner, PhD, and David J. Satin, MD Some allopathic clinicians’ biases influence the information they draw upon to make decisions and offer recommendations. AMA J Ethics. 2022;24(5):E368-375. doi: 10.1001/amajethics.2022.368.